Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Margetuximab in Combination With Tucatinib and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer

NCT05227131 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT05227131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05227131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Margetuximab in Combination With Tucatinib and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Withdrawn
Start date
May 15, 2022
Completion date
October 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, her2-positive breast cancer, metastatic breast cancer